[go: up one dir, main page]

BRPI0819081A2 - Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento - Google Patents

Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento

Info

Publication number
BRPI0819081A2
BRPI0819081A2 BRPI0819081A BRPI0819081A2 BR PI0819081 A2 BRPI0819081 A2 BR PI0819081A2 BR PI0819081 A BRPI0819081 A BR PI0819081A BR PI0819081 A2 BRPI0819081 A2 BR PI0819081A2
Authority
BR
Brazil
Prior art keywords
inhibiting
patient
treating
preparing
treatment
Prior art date
Application number
Other languages
English (en)
Inventor
Jean Philippe Combal
Elisabeth Latour
Harun Takruri
Original Assignee
Fovea Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fovea Pharmaceuticals Sa filed Critical Fovea Pharmaceuticals Sa
Publication of BRPI0819081A2 publication Critical patent/BRPI0819081A2/pt
Publication of BRPI0819081A8 publication Critical patent/BRPI0819081A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0819081A 2007-10-08 2008-10-08 Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento BRPI0819081A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07360047 2007-10-08
PCT/EP2008/008482 WO2009046967A1 (en) 2007-10-08 2008-10-08 Aqueous ophthalmic formulations

Publications (2)

Publication Number Publication Date
BRPI0819081A2 true BRPI0819081A2 (pt) 2015-04-22
BRPI0819081A8 BRPI0819081A8 (pt) 2016-08-30

Family

ID=40251764

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819081A BRPI0819081A8 (pt) 2007-10-08 2008-10-08 Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento

Country Status (12)

Country Link
US (1) US20120028910A1 (pt)
EP (1) EP2195033A1 (pt)
JP (1) JP5640207B2 (pt)
CN (1) CN101820917B (pt)
AU (1) AU2008309923B2 (pt)
BR (1) BRPI0819081A8 (pt)
CA (1) CA2702082A1 (pt)
EA (1) EA019867B1 (pt)
MX (1) MX2010003774A (pt)
NZ (1) NZ584275A (pt)
WO (1) WO2009046967A1 (pt)
ZA (1) ZA201003195B (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
CA2840734A1 (en) * 2011-06-29 2013-01-03 Allergan, Inc. Macrogol 15 hydroxystearate formulations
US20130029919A1 (en) * 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2013138343A1 (en) 2012-03-16 2013-09-19 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
EP2825207B1 (en) 2012-03-16 2020-08-19 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
FR2988297B1 (fr) 2012-03-22 2014-03-28 Thea Lab Solution ophtalmique aqueuse a base de ciclosporine a sans conservateur
KR101211902B1 (ko) * 2012-04-30 2012-12-13 주식회사 휴온스 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
KR102140989B1 (ko) 2012-05-03 2020-08-04 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
AU2013256064B2 (en) 2012-05-03 2018-01-04 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9889208B2 (en) 2012-05-04 2018-02-13 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
PT2877184T (pt) * 2012-07-27 2019-12-02 Glia Llc Composições e tratamento para doenças e distúrbios oculares
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
KR101363776B1 (ko) * 2012-12-21 2014-02-17 이상필 사이클로스포린을 포함하는 투명 점안액 조성물
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150352176A1 (en) * 2014-06-06 2015-12-10 Newport Research, Inc. Oil-free and fat-free aqueous suspensions of cyclosporin
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
JP6671141B2 (ja) * 2014-10-21 2020-03-25 大日本住友製薬株式会社 懸濁液剤
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
KR20240126072A (ko) 2015-01-27 2024-08-20 더 존스 홉킨스 유니버시티 점막표면에서 활성제의 향상된 수송을 위한 저장성 하이드로겔 제제
HK1248570A1 (zh) 2015-05-29 2018-10-19 西德奈克西斯公司 D2o稳定化的药物制剂
WO2016205071A1 (en) * 2015-06-18 2016-12-22 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR101635915B1 (ko) * 2016-02-15 2016-07-04 삼천당제약주식회사 사이클로스포린과 히알루론산 또는 이의 염을 포함하는 수용액 형태의 안과용 조성물
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10711070B1 (en) * 2017-03-22 2020-07-14 The United States Of America As Represented By The Secretary Of The Army Method for preparing spherical celluloid beads
SG11201910085UA (en) 2017-05-11 2019-11-28 Nevakar Inc Atropine pharmaceutical compositions
RU2668713C1 (ru) * 2018-03-16 2018-10-02 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский институт глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации Способ лечения центральных язв роговицы бактериальной и герпетической этиологии
CN112272558A (zh) 2018-04-24 2021-01-26 阿勒根公司 盐酸毛果芸香碱用于治疗眼部病症的用途
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
JP2020152674A (ja) * 2019-03-20 2020-09-24 株式会社リコー 難水溶性化合物の可溶化物の製造方法
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain
EP4433053A4 (en) 2021-11-17 2025-09-17 Lenz Therapeutics Operations Inc ACECLIDINE DERIVATIVES, THEIR COMPOSITIONS AND METHODS OF USE
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2072015B (en) * 1980-03-21 1983-12-21 Wellcome Found Compositions containing polymyxin
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
JPS59101478A (ja) * 1982-11-29 1984-06-12 Sunstar Inc リグスチライドを安定に配合した水系組成物
JPH0558906A (ja) * 1991-09-06 1993-03-09 Sankyo Co Ltd シクロスポリン点眼製剤
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US6465016B2 (en) * 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
JP2000143542A (ja) * 1998-11-10 2000-05-23 Wakamoto Pharmaceut Co Ltd 難溶性免疫抑制剤含有ｏ／ｗエマルジョン製剤
EP1225879A2 (en) * 1999-10-22 2002-07-31 Orbon Corporation Ophthalmic formulation of dopamine antagonists
PT1142566E (pt) * 2000-04-07 2004-02-27 Medidom Lab Formulacao oftalmica topica na forma de uma solucao aquosa e uso de uma ciclosporina em associacao com acido hialuronico ou um de seus sais e com polisorbato 80
JP2005154334A (ja) * 2003-11-25 2005-06-16 Toa Yakuhin Kk アズレンスルホン酸塩水溶液剤
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
WO2006073786A2 (en) * 2004-12-30 2006-07-13 Bausch & Lomb Incorporated Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US20070087962A1 (en) * 2005-10-17 2007-04-19 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
DE102006051512A1 (de) * 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye

Also Published As

Publication number Publication date
WO2009046967A1 (en) 2009-04-16
JP5640207B2 (ja) 2014-12-17
EA201000441A1 (ru) 2010-10-29
NZ584275A (en) 2012-06-29
AU2008309923A1 (en) 2009-04-16
EP2195033A1 (en) 2010-06-16
BRPI0819081A8 (pt) 2016-08-30
JP2010540671A (ja) 2010-12-24
AU2008309923B2 (en) 2014-04-03
EA019867B1 (ru) 2014-06-30
MX2010003774A (es) 2010-04-27
CA2702082A1 (en) 2009-04-16
US20120028910A1 (en) 2012-02-02
ZA201003195B (en) 2011-02-23
CN101820917B (zh) 2013-01-02
HK1147937A1 (en) 2011-08-26
CN101820917A (zh) 2010-09-01

Similar Documents

Publication Publication Date Title
BRPI0819081A2 (pt) Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento
BRPI0905073A2 (pt) Depósito implantável de drogas para reduzir, prevenir ou tratar dor em um paciente em necessidade de tal tratamento e método para tratar dor aguda.
BRPI0821299A2 (pt) Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição.
BRPI0906156A2 (pt) sistema de tratamento de alivio de carga e de pressão reduzida, dispositivo de tratamento de alívio de carga e de pressão reduzida, método de fabricação de um dispositivo de tratameno de alívio de carga e de pressão reduzida, método para o tratamento de um ferimento plantar no pé de um paciente e método para o tratamento de um ferimento plantar e um ferimento dorsal no pé de um paciente.
BR112014008485A2 (pt) dispositivo para cirurgia no olho humano, e, processo para tratamento cirúrgico a laser do olho humano
BR112012010261A2 (pt) dispositivo de microcânula, e, métodos para tratar o espaço supracoroidal de um olho, para tratar a região posterior de um olho e para tratar os tecidos dentro ou adjacentes ao espaço supracoroidal de um olho
BR112015007758A2 (pt) dispositivo para um tratamento médico de uma esclera, método para tratar a esclera em um sujeito e método para tratar uma alteração patológica ou doença do olho.
BRPI0909569A2 (pt) sistema de tratamento com pressão reduzida de ferimentos para o tratamento de um sítio de tecido em um paciente, pano cirúrgico para ferimentos, método para o tratamento de um ferimento em um paciente com pressão reduzida e método de manufaturar de um pano cirúrgico para ferimento
BRPI0904957A2 (pt) Depósito de droga implantável útil para reduzir, prevenir ou tratando dor pós-operatória em um paciente e métodos de tratar ou prevenir dor pós-operatória em um paciente e de produzir um depósito de droga implantável.
BRPI0811534A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticametne aceitável do mesmo.
BRPI0810118A2 (pt) Método para tratar doença, método para efetuar profilaxia contra caa, uso de um agente, método para reduzir amilóide vascular em um paciente, e, kit para tratamento
BRPI0720031A2 (pt) Aparelho de tratamento do corpo humano ou animal por emissão de flashes luminosos, e, processo de segurança do funcionamento de um aparelho de tratamento do corpo humano ou animal por emissão de flashes luminosos.
BRPI0920102A2 (pt) Compostos de piridina, processo para preparar os compostos, agente, e, processo para combater vegetação indesejada
WO2008052081A3 (en) Photochemical therapy to affect mechanical and/or chemical properties of body tissue
BRPI0920443A2 (pt) compostos de piperazina, agente, e, processo para combater vegetacao indesejavel.
BRPI0921687A2 (pt) Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero.
BR112012021522A2 (pt) bráquete ortodôntico para um sistema ortodôntico, sistema de bráquete ortodôntico, kit ortodôntico, processo para fabricar um bráquete ortodôntico e método para tratar a mordida de um paciente humano
BRPI1013396A2 (pt) composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto.
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
BRPI0924622A2 (pt) composições para tratamento de tecidos, processo de fabricação, e método de uso.
BRPI0909984A2 (pt) "método de tratamento dos olhos para prevenção de presbiopia e/ou começo de glaucoma e dispositivo para realizar tratamento dos olhos para prevenção de presbiopia e/ou começo de glaucoma"
BR112012002246A2 (pt) composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente
BRPI0906805A2 (pt) Composto, processo para preparar o enanciômero puro, composição farmacêutica, uso do enanciômero puro, métodos para prevenir ou tratar doença em um animal de sangue quente, e, combinação
WO2010071826A3 (en) Methods for treating osteoclast-related disease, compounds and compositions thereof
BRPI0908229A2 (pt) método para dispensar iontoforeticamente um corticoesteróide, derivado de corticoesteróide, pró-droga ou sal no olho de um paciente, kit para dispensar iontoforeticamente dexametasona no olho de um paciente, formulação de dexametasona, dispositivo para dispensar dexametasona, e, método para tratar uma doença oftálmica sensível a corticoesteróide em um mamífero.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: FOVEA PHARMACEUTICALS (FR)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.